cabozantinib
Selected indexed studies
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. (N Engl J Med, 2025) [PMID:39282913]
- Cabozantinib in progressive medullary thyroid cancer. (J Clin Oncol, 2013) [PMID:24002501]
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. (N Engl J Med, 2018) [PMID:29972759]
_Worker-drafted node — pending editorial review._
Connections
cabozantinib is a side effect of
Sources
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. (2025) pubmed
- Cabozantinib in progressive medullary thyroid cancer. (2013) pubmed
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. (2018) pubmed
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) pubmed
- Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. (2023) pubmed
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. (2016) pubmed
- Cabozantinib as an emerging treatment for sarcoma. (2020) pubmed
- Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) pubmed
- Cabozantinib for the treatment of hepatocellular carcinoma. (2019) pubmed
- Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins. (2025) pubmed